Status:
COMPLETED
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Lead Sponsor:
Hospital de Infecciosas Francisco Javier Muniz
Conditions:
SARS-Associated Coronavirus
Covid19
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
Detailed Description
This study aims to use convalescent plasma as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit. Donors must have anti-S...
Eligibility Criteria
Inclusion
- Age: 18 years or more.
- Patient with Covid-19 confirmed with nuclear acid testing
- Critically ill patients with Covid-19 on mechanical ventilation. Potencially critically ill patients (with acute respiratory distress syndrome, septic shock and/or multiple organ failure) with Covid-19.
- Diagnosed with acute respiratory distress syndrome.
- Informed consent.
Exclusion
- No consent.
- Symptoms for a period longer than 20 days.
- Not detectable by acid nuclear testing within 48 hours prior to elegibility.
- Descompensated congestive heart failure, in which receiving 500ml of intrasvascular volume signifies a life risk.
- History of severe adverse events or anaphylaxis to plasma components
Key Trial Info
Start Date :
June 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 19 2021
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT04468009
Start Date
June 25 2020
End Date
June 19 2021
Last Update
August 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Francisco Javier Muñiz
Ciudad Autonoma de Buenos Aire, Argentina, 1663